Potential risk factors for acquisition of hepatitis C virus in patients with chronic hepatitis C infection in a referral population of an academic medical center

1995 ◽  
Vol 108 (4) ◽  
pp. A1065
Author(s):  
SL Flamm ◽  
S Chopra
2019 ◽  
Vol 6 (5) ◽  
Author(s):  
Daniel Winetsky ◽  
Jason Zucker ◽  
Jacek Slowikowski ◽  
Matthew Scherer ◽  
Elizabeth C Verna ◽  
...  

Abstract In December 2017, our academic medical center implemented universal hepatitis C virus screening among adult hospitalized patients. We reviewed charts of patients screening positive outside the birth cohort (1945–1965) in the first 6 months after implementation. Documented risk factors were common in younger patients but rare in patients born before 1945.


Author(s):  
Manal Khudder Abdul Razak

Objective: Patients who frequently receive blood have high risk of hepatitis C virus (HCV) infection. This study aimed to evaluate the prevalence of HCV infection and potential risk factors among multiply transfused patients.Methods: A cross-sectional retrospective study was conducted in the hemophilia unit in Medical City in Baghdad, between June 1, 2016, and January 1, 2017. After taking consents and approval of ethical comity, the medical records of 1158 patients with hemophilia A and B, von Willebrand disease (vWD), thrombasthenia, Factors VII, X, and XIII deficiencies, and hypofibrinogenemia were analyzed for the presence of HCV antibody using (enzyme-linked immunosorbent assay). Cases of hemophilia were classified into mild, moderate, and severe.Results: The prevalence of HCV infection was 13.2%. Of total, 595 (51.4%) patients had hemophilia A and 99 (16.6%) were anti-HCV positive, while 225 (19.4%) had hemophilia B and 28 (12.4%) were antibody positive compared to 9 (7%) in vWD. Of those with hemophilia A, 515 (86.6%) had severe hemophilia, and 32 (32.32%) cases had acquired HCV infection after 1996 (after introduction of HCV screening in blood banks in Iraq). There was a statistically significant association with treatment by Factor VIII only.Conclusion: The prevalence of HCV in patients with inherited bleeding disorder is 13.2%. In this study, it was found that multitransfusion is the only predictor for HCV infection in this group of patients. 


Author(s):  
Manal Khudder Abdul Razak

Objective: Patients who frequently receive blood have high risk of hepatitis C virus (HCV) infection. This study aimed to evaluate the prevalence of HCV infection and potential risk factors among multiply transfused patients.Methods: A cross-sectional retrospective study was conducted in the hemophilia unit in Medical City in Baghdad, between June 1, 2016, and January 1, 2017. After taking consents and approval of ethical comity, the medical records of 1158 patients with hemophilia A and B, von Willebrand disease (vWD), thrombasthenia, Factors VII, X, and XIII deficiencies, and hypofibrinogenemia were analyzed for the presence of HCV antibody using (enzyme-linked immunosorbent assay). Cases of hemophilia were classified into mild, moderate, and severe.Results: The prevalence of HCV infection was 13.2%. Of total, 595 (51.4%) patients had hemophilia A and 99 (16.6%) were anti-HCV positive, while 225 (19.4%) had hemophilia B and 28 (12.4%) were antibody positive compared to 9 (7%) in vWD. Of those with hemophilia A, 515 (86.6%) had severe hemophilia, and 32 (32.32%) cases had acquired HCV infection after 1996 (after introduction of HCV screening in blood banks in Iraq). There was a statistically significant association with treatment by Factor VIII only.Conclusion: The prevalence of HCV in patients with inherited bleeding disorder is 13.2%. In this study, it was found that multitransfusion is the only predictor for HCV infection in this group of patients. 


2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S930-S930
Author(s):  
Harry Ross Powers ◽  
Walter Hellinger ◽  
Cherise Cortese ◽  
Hani M Wadei

Abstract Background There are few studies of histologic acute graft pyelonephritis (HAGPN) following kidney transplant (KT). The goals of this study are to determine incidence, identify potential risk factors and describe outcomes of HAGPN in a large cohort of KT recipients. Methods Renal allograft biopsies of all patients undergoing first KT at our medical center between 2008 and 2017 were reviewed. HAGPN was defined as the presence of neutrophils within the interstitium and tubules (casts). Medical charts of patients with HAGPN were reviewed. Episodes of bacteriuria (≥10:5 cfu/mL growth in culture) were classified as urinary tract infection (UTI) or asymptomatic bacteruria (ASB) based upon documented symptoms. An episode of acute rejection was defined as pulse parenteral immunosuppressive therapy for histologic evidence of rejection. Results HAGPN was identified in 43 of 1,391 (3.1%) KT recipients at a median of 298 days post-transplant. There were no significant differences between recipient age or gender, donor age or transplant type (deceased, living related, living unrelated) between recipients with and without HAGPN. Urologic malformation was diagnosed in 14 (33%) by day 30 post-transplant. Twenty-five (58%), 17 (40%), and 13 (30%) sustained one or more episodes of acute rejection, UTI and ASB, respectively, prior to HAGPN. At diagnosis of HAGPN, 28 (65%), 7 (16%), and 16 (37%) had histologic evidence of rejection, UTI and ASB, respectively. Twenty-two (51%) and 37 (86%) were treated with pulse immunosuppression and antibiotics, respectively. Median nadir serum creatinine before HAGPN was 1.1 mg/day while median serum creatinine at 6 and 12 months after HAGPN were 1.5 and 1.6. Three patients (7%) developed graft failure within 1 year after HAGPN. Conclusion HAGPN is an infrequent complication of KT. A majority of patients with HAGPN have histologic evidence of rejection and either UTI or ASB at diagnosis, though over 40% have neither UTI nor ASB. When rejection accompanying HAGPN is routinely treated with pulse immunosuppression and antibiotic therapy is administered, graft function is preserved for most patients but a minority (7%) loses graft function within 1 year. Potential risk factors to be assessed in further study include post-transplant urologic dysfunction, acute rejection and UTI. Disclosures All authors: No reported disclosures.


2017 ◽  
Vol 29 (5) ◽  
pp. 292-298 ◽  
Author(s):  
Brianne M. Ritchie ◽  
Beth A. Hirning ◽  
Craig A. Stevens ◽  
Steven A. Cohen ◽  
Jeremy R. DeGrado

Sign in / Sign up

Export Citation Format

Share Document